Löfgren’s syndrome (LS) is an acute form of sarcoidosis characterized by a genetic association with HLA-DRB1*03 (HLA-DR3) and an accumulation of CD4+ T cells of unknown specificity in the bronchoalveolar lavage (BAL). Here, we screened related LS-specific TCRs for antigen specificity and identified a peptide derived from NAD-dependent histone deacetylase hst4 (NDPD) of Aspergillus nidulans that stimulated these CD4+ T cells in an HLA-DR3–restricted manner. Using ELISPOT analysis, a greater number of IFN-γ– and IL-2–secreting T cells in the BAL of DR3+ LS subjects compared with DR3+ control subjects was observed in response to the NDPD peptide. Finally, increased IgG antibody responses to A. nidulans NDPD were detected in the serum of DR3+ LS subjects. Thus, our findings identify a ligand for CD4+ T cells derived from the lungs of LS patients and suggest a role of A. nidulans in the etiology of LS.
Materials, methods; Figure S1. 1H NMR spectrum of MT-1; Figure S2. 1H NMR spectrum of MT-2; Figure S3. 1H NMR spectrum of MT-3; Figure S4. 1H NMR spectrum of MT-4; Figure S5. 1H NMR spectrum of MT-5; Figure S6. 1H NMR spectrum of MT-6; Figure S7. Enthalpy kinetics of MT-4 -TG2 interaction as measured by Isothermal Titration Calorimetry (ITC); Figure S8. Effects of TG-53 and MT-4 on TGase activity; Figure S9. TIRF analysis of β1 integrin receptors distribution upon cell treatment with SMIs at the indicated concentrations and adhesion onto FN coated plates; Figure S10. Flow cytometry analysis of integrin β1 plasma membrane expression; Figure S11. Dose response effects induced by TG2-FN inhibitors on FAK phosphorylation; Figure S12. Experimental design for in vivo assay testing the activity of MT4; Figure S13. Cell cycle distribution and apoptosis of OVCAR5 cells primed with MT-4 or TG53 for 72 hours before treatment with paclitaxel (PTX).